3 results
MK-1439 is a promising NNRTI to be used in combination with other antiretrovirals (ARTs) for the treatment of HIV infection. It is a potent inhibitor of HIV-1 replication in vitro and is active against both wild type virus and most common NNRTI…
The primary objective of the trial is to demonstrate non-inferiority of treatment with TMC278 when administered as 75 mg q.d. compared to the control group (EFV) in regard to the proportion of virologic responders (plasma viral load < 50 HIV-…
3.1 Primary objectiveThe primary objective of the study is to evaluate the efficacy of bimekizumab administered scQ2W for 12 weeks compared to CZP in the treatment of subjects with active AS.3.2 Secondary objectivesThe secondary objectives of the…